» Articles » PMID: 34673772

Changes in the Associations of Race and Rurality with SARS-CoV-2 Infection, Mortality, and Case Fatality in the United States from February 2020 to March 2021: A Population-based Cohort Study

Abstract

Background: We examined whether key sociodemographic and clinical risk factors for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection and mortality changed over time in a population-based cohort study.

Methods And Findings: In a cohort of 9,127,673 persons enrolled in the United States Veterans Affairs (VA) healthcare system, we evaluated the independent associations of sociodemographic and clinical characteristics with SARS-CoV-2 infection (n = 216,046), SARS-CoV-2-related mortality (n = 10,230), and case fatality at monthly intervals between February 1, 2020 and March 31, 2021. VA enrollees had a mean age of 61 years (SD 17.7) and were predominantly male (90.9%) and White (64.5%), with 14.6% of Black race and 6.3% of Hispanic ethnicity. Black (versus White) race was strongly associated with SARS-CoV-2 infection (adjusted odds ratio [AOR] 5.10, [95% CI 4.65 to 5.59], p-value <0.001), mortality (AOR 3.85 [95% CI 3.30 to 4.50], p-value < 0.001), and case fatality (AOR 2.56, 95% CI 2.23 to 2.93, p-value < 0.001) in February to March 2020, but these associations were attenuated and not statistically significant by November 2020 for infection (AOR 1.03 [95% CI 1.00 to 1.07] p-value = 0.05) and mortality (AOR 1.08 [95% CI 0.96 to 1.20], p-value = 0.21) and were reversed for case fatality (AOR 0.86, 95% CI 0.78 to 0.95, p-value = 0.005). American Indian/Alaska Native (AI/AN versus White) race was associated with higher risk of SARS-CoV-2 infection in April and May 2020; this association declined over time and reversed by March 2021 (AOR 0.66 [95% CI 0.51 to 0.85] p-value = 0.004). Hispanic (versus non-Hispanic) ethnicity was associated with higher risk of SARS-CoV-2 infection and mortality during almost every time period, with no evidence of attenuation over time. Urban (versus rural) residence was associated with higher risk of infection (AOR 2.02, [95% CI 1.83 to 2.22], p-value < 0.001), mortality (AOR 2.48 [95% CI 2.08 to 2.96], p-value < 0.001), and case fatality (AOR 2.24, 95% CI 1.93 to 2.60, p-value < 0.001) in February to April 2020, but these associations attenuated over time and reversed by September 2020 (AOR 0.85, 95% CI 0.81 to 0.89, p-value < 0.001 for infection, AOR 0.72, 95% CI 0.62 to 0.83, p-value < 0.001 for mortality and AOR 0.81, 95% CI 0.71 to 0.93, p-value = 0.006 for case fatality). Throughout the observation period, high comorbidity burden, younger age, and obesity were consistently associated with infection, while high comorbidity burden, older age, and male sex were consistently associated with mortality. Limitations of the study include that changes over time in the associations of some risk factors may be affected by changes in the likelihood of testing for SARS-CoV-2 according to those risk factors; also, study results apply directly to VA enrollees who are predominantly male and have comprehensive healthcare and need to be confirmed in other populations.

Conclusions: In this study, we found that strongly positive associations of Black and AI/AN (versus White) race and urban (versus rural) residence with SARS-CoV-2 infection, mortality, and case fatality observed early in the pandemic were ameliorated or reversed by March 2021.

Citing Articles

Recognising the heterogeneity of Indigenous Peoples during the COVID-19 pandemic: a scoping review across Canada, Australia, New Zealand and the USA.

Lyeo J, Liberda E, Ahmed F, Charania N, Moriarity R, Tsuji L BMJ Public Health. 2025; 2(2):e001341.

PMID: 40018612 PMC: 11816692. DOI: 10.1136/bmjph-2024-001341.


Urban and Rural Disparities in COVID-19 Outcomes in the United States: A Systematic Review.

Kang J, Quigley D, Chastain A, Ma H, Shang J, Stone P Med Care Res Rev. 2024; 82(2):119-136.

PMID: 39655727 PMC: 11871999. DOI: 10.1177/10775587241298566.


Understanding racial/ethnic disparities in COVID-19 mortality using a novel metric: COVID excess mortality percentage.

Yuan A, Atanasov V, Barreto N, Franchi L, Whittle J, Weston B Am J Epidemiol. 2024; 193(6):853-862.

PMID: 38375671 PMC: 11145910. DOI: 10.1093/aje/kwae007.


Risk factors for SARS-CoV-2 infection during the early stages of the COVID-19 pandemic: a systematic literature review.

Harris M, Hart J, Bhattacharya O, Russell F Front Public Health. 2023; 11:1178167.

PMID: 37583888 PMC: 10424847. DOI: 10.3389/fpubh.2023.1178167.


Early Outcomes of SARS-CoV-2 Infection in a Multisite Prospective Cohort of Inpatient Veterans.

Ross J, Sugimoto J, Timmons A, Adams J, Deardoff K, Korpak A Open Forum Infect Dis. 2023; 10(7):ofad330.

PMID: 37484899 PMC: 10358428. DOI: 10.1093/ofid/ofad330.


References
1.
Fan V, Dominitz J, Eastment M, Locke E, Green P, Berry K . Risk Factors for Testing Positive for Severe Acute Respiratory Syndrome Coronavirus 2 in a National United States Healthcare System. Clin Infect Dis. 2020; 73(9):e3085-e3094. PMC: 7665412. DOI: 10.1093/cid/ciaa1624. View

2.
Peterson K, Anderson J, Boundy E, Ferguson L, McCleery E, Waldrip K . Mortality Disparities in Racial/Ethnic Minority Groups in the Veterans Health Administration: An Evidence Review and Map. Am J Public Health. 2018; 108(3):e1-e11. PMC: 5803811. DOI: 10.2105/AJPH.2017.304246. View

3.
Deyo R, Cherkin D, Ciol M . Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992; 45(6):613-9. DOI: 10.1016/0895-4356(92)90133-8. View

4.
Perez-Belmonte L, Torres-Pena J, Lopez-Carmona M, Ayala-Gutierrez M, Fuentes-Jimenez F, Jorge Huerta L . Mortality and other adverse outcomes in patients with type 2 diabetes mellitus admitted for COVID-19 in association with glucose-lowering drugs: a nationwide cohort study. BMC Med. 2020; 18(1):359. PMC: 7666969. DOI: 10.1186/s12916-020-01832-2. View

5.
Charlson M, Pompei P, Ales K, MacKenzie C . A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40(5):373-83. DOI: 10.1016/0021-9681(87)90171-8. View